NeOnc Technologies Secures Board Approval for $50 Million Strategic Partnership with Quazar Investment

CALABASAS, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage biotechnology company advancing transformative treatments for brain and central nervous system cancers, today announced it has achieved a key milestone toward closing its previously announced strategic transaction with Quazar Investment: formal approval from NeOnc’s Board of Directors. On June 30, 2025, NeOnc’s Board unanimously approved the company’s participation in the contemplated $50 ...